Psoriatic Arthritis

This post-hoc analysis demonstrated an association between work productivity and stringent disease control criteria for those with psoriatic arthritis.

These data, presented at ACR 2024, demonstrate that response was maintained at 2 years among those with psoriatic arthritis who responded to bimekizumab at Week 16.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.

Malignancy-related IBP has distinct features: shorter diagnosis time, higher ESR/CRP/LDH, lower hemoglobin, and often involves metastasis or paraneoplastic causes.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.

Secukinumab is best for severe skin involvement, while adalimumab improves synovitis in PsA. Both are effective, but larger studies are needed for long-term outcomes.

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.

A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.

BIMZELX was previously approved for treating moderate-to-severe plaque psoriasis.

Gender, age, and disease duration significantly affected symptom variations.

Extended follow-up with more cases is ongoing and will allow risk factors for psoriatic arthritis to also be further explored.

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.

All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

Types of occupation did not significantly affect response to treatment.

Notably, people with fewer vaccine doses were more likely to experience post-acute sequelae of COVID-19.

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

Investigators analyzed levels of CXCL10, MMP3, S100A8, ACP5, and CCL2 in patients treated with biologics and methotrexate.

The rheumatology month in review emphasize's bimekizumab's efficacy in treating PsA and new risk factors and mitigators for developing gout or hyperuricemia.

Higher risk associations also included being a current smoker and socioeconomic deprivation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.